Sign In
Buy ABBV
$227.23
+2.30 (+1.02%)
At Close: Jun 05, 2026
Is AbbVie's Dividend Yield Safe?
01:32pm, Thursday, 06'th Jul 2023
AbbVie is a top-shelf dividend stock. However, the company's free cash flows are set to decline this year in response to biosimilar competition.
Got $5,000? These Are 3 of the Best Stocks to Buy in July
09:45am, Thursday, 06'th Jul 2023
AbbVie is a heavily discounted healthcare stock whose business is in fine shape. Verizon offers a mouthwatering dividend at a very manageable payout ratio.
AbbVie: Use This Buying Opportunity (Rating Upgrade)
08:00am, Thursday, 06'th Jul 2023
AbbVie stock has been upgraded to a buy again due to its attractive yield and less demanding valuation, despite expectations of a down year in 2023. The healthcare company is seen as a resilient inves
The 7 Best Forever Stocks to Buy for July 2023
03:16pm, Wednesday, 05'th Jul 2023
With the latest encouraging read on inflation sending the market on a high to end the first half of this year, the idea of acquiring the best forever stocks may seem overly cautious. After all, with s
AbbVie braces for increased Humira competition from cheaper biosimilar
10:14am, Wednesday, 05'th Jul 2023
AbbVie is about to face stiffer competition for its blockbuster rheumatoid arthritis drug Humira from a new biosimilar about to be launched in the US. Celltrion Healthcare, a South Korean company, has
Celltrion launches biosimilar of AbbVie's blockbuster drug Humira in US
07:34am, Wednesday, 05'th Jul 2023
South Korea's Celltrion Healthcare has launched a copycat version to AbbVie Inc's Humira at about a 5% discount, adding to the growing competition for the blockbuster rheumatoid arthritis drug in the
3 Spectacular Dividend Stocks to Buy in July
08:14am, Tuesday, 04'th Jul 2023
AbbVie is a Dividend King with a high yield. Bristol Myers Squibb is an underrated bargain.
India's Biocon Biologics launches biosimilar for AbbVie's Humira in US
01:59pm, Monday, 03'rd Jul 2023
India's Biocon Biologics said on Monday it has launched a biosimilar version of AbbVie's blockbuster rheumatoid arthritis drug Humira in the United States.
Fresenius launches biosimilar version of AbbVie's Humira at 5% discount
10:59am, Monday, 03'rd Jul 2023
The generic drug unit of Germany's Fresenius said on Monday the price for Idacio, its copycat version of Abbvie's top-selling rheumatoid arthritis drug, will be at a 5% discount to Humira's list price
Merck and AbbVie Are Facing Big Patent Cliffs, But Here's Why Both Are Still Buys
09:15am, Monday, 03'rd Jul 2023
Each has a blockbuster therapy that is likely facing declining sales. But both companies' pipelines have more than 100 programs.
Coherus BioSciences launches biosimilar version of AbbVie's blockbuster Humira
09:12am, Monday, 03'rd Jul 2023
Coherus BioSciences said on Monday it has launched a copycat version of AbbVie's Humira in the United States at a discount of over 85% to the blockbuster arthritis drug.
3 Magnificent Dividend Stocks to Buy Hand Over Fist in July
05:52am, Monday, 03'rd Jul 2023
AbbVie is a Dividend King that's poised to deliver robust long-term growth. Brookfield Renewable should benefit tremendously from the increased demand for clean energy.
Could This New Drug Be a Blockbuster for These 2 Pharma Collaborators?
09:30am, Sunday, 02'nd Jul 2023
In clinical trials, epcoritamab proved highly effective in treating a certain kind of lymphoma. The cancer drug, developed jointly by AbbVie and Genmab, has a huge potential market.
Sandoz launches rival version of AbbVie's arthritis drug Humira
12:20am, Saturday, 01'st Jul 2023
Swiss drugmaker Sandoz said on Saturday it had launched a biosimilar version of AbbVie Inc's big selling arthritis treatment Humira, adding to U.S. competition for the drug that started in January.
For AbbVie's blockbuster Humira, cheaper competitors pose surprisingly little threat, analysts say
01:28pm, Friday, 30'th Jun 2023
AbbVie's ABBV, +1.53% rheumatoid arthritis drug Humira, one of the top-selling biopharmaceutical products of all time, will have new lower-cost competition starting Saturday. But even as nearly identi
